eligibility_summary
Inclusion: R/R cHL, PTCL (incl sALCL), B‑cell neoplasms, select PCL. A/B require CD30≥1% (except cHL/ALCL). C: CD30‑agnostic, cHL after ≥3 lines, ASCT refused/ineligible, prior/ineligible anti‑PD‑1, PTCL ≥2 lines or ≥1 if no options, sALCL relapse after ≥2 lines incl BV or after 1 A+CHP. ECOG≤1, FDG‑PET‑avid measurable (not for PCL). Exclusion: >2 BV lines, other cancer <3y, CNS, ASCT<12w, allo‑SCT<100d/GVHD/IS, CMV reactivation, ≥G2 lung/ILD or steroid‑treated lung dz.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT06120504 tests PF-08046045 (SGN-35T), an investigational CD30-directed antibody-drug conjugate (ADC) given IV as monotherapy in adults with relapsed/refractory lymphomas. Mechanism: a monoclonal antibody binds CD30 on tumor cells, is internalized, and releases a cytotoxic payload to induce cell death (ADC immunotherapy). Phase 1 aims to define dose/schedule and assess safety, PK/PD, and antitumor activity. Targets: CD30 (TNFRSF8) on malignant lymphocytes—classical Hodgkin lymphoma (Reed–Sternberg cells), systemic anaplastic large cell lymphoma, peripheral T‑cell lymphoma, certain primary cutaneous T‑cell lymphomas, and CD30‑positive subsets of diffuse large B‑cell lymphoma—engaging the CD30 pathway on activated T/B cells.